Preferred Label : Anti-CLDN18.2 Antibody-drug Conjugate TQB2103;
NCIt synonyms : Anti-CLDN18.2 ADC TQB2103; Anti-claudin 18.2 ADC TQB2103;
NCIt definition : An antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody directed
against the tumor-associated antigen (TAA) claudin 18.2 (CLDN18.2; A2 isoform of claudin-18)
conjugated via a cleavable linker, to an undisclosed cytotoxic agent, with potential
antineoplastic activity. Upon administration, anti-CLDN18.2 ADC TQB2103 specifically
targets and binds to CLDN18.2 expressed on tumor cells. Upon endocytosis and the transfer
to lysosomes, the payload is released via enzymatic cleavage of the linker. The cytotoxic
agent causes DNA damage in and kills CLDN18.2-expressing tumor cells. Through bystander
effect, TQB2103 is also able to kill adjacent tumor cells. CLDN18.2, a tight junction
protein and stomach-specific isoform of claudin-18, is expressed on a variety of tumor
cells. Its expression in healthy tissues is strictly confined to short-lived differentiated
epithelial cells of the gastric mucosa.;
Molecule name : TQB 2103; TQB-2103;
NCI Metathesaurus CUI : CL1915154;
Origin ID : C200908;
UMLS CUI : C5854617;
Semantic type(s)
- concept_is_in_subset
